Clinical Trials

Status
Published

1445 Results

Open
Accrual
0%
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Status Notes
Activated 9/17/18.
Research Committee(s)
Genitourinary Cancer
Other
Symptom Control and Quality of Life
Activated
09-17-2018
Open
Accrual
0%
SWOG Clinical Trial Number
S1706

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Status Notes
Activation, Effective 9/12/2018, 2:00 pm CT
Research Committee(s)
Breast Cancer
Activated
09-12-2018
ClinicalTrials.gov Registry Number
NCT03598257
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1701

A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Status Notes
This study is open to accrual effective 8/9/18.
Research Committee(s)
Lung Cancer
Activated
08-09-2018
Open
Phase
II
Accrual
2%
SWOG Clinical Trial Number
S1712
Open
Accrual
41%
SWOG Clinical Trial Number
S1702

A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis

Status Notes
This study is active for patient participation effective 3/8/18 at 2:00 p.m. Eastern.
Research Committee(s)
Myeloma
Activated
03-08-2018
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA8153

Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Status Notes
This study is open to accrual effective February 8, 2018.
Research Committee(s)
Genitourinary Cancer
Activated
02-08-2018
Closed
Phase
II
Accrual
64%
SWOG Clinical Trial Number
S1400K

A PHASE II STUDY OF ABBV-399 (PROCESS II) IN PATIENTS WITH C-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Status Notes
Effective on 10/18/18 at 1:00 pm PST, S1400K will be temporarily closed to accrual.

Effective on 2/5/18 at 2:00 pm PST, S1400K will be activated.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Research Committee(s)
Lung Cancer
Activated
02-05-2018
Open
Accrual
5%
SWOG Clinical Trial Number
S1612

A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older

Status Notes
This study is temporarily closed to accrual, effective 10/22/18.
Research Committee(s)
Leukemia
Activated
12-22-2017
Open
Phase
III
Open
Accrual
21%
SWOG Clinical Trial Number
S1619

A Feasibility Trial of Neoadjuvant Cisplatin - Pemetrexed - Atezolizumab with Adjuvant Maintenance Atezolizumab in Resectable Malignant Pleural Mesothelioma

Status Notes
This study is open to accrual effective November 3, 2017 at 2:00 p.m. Eastern.
Research Committee(s)
Lung Cancer
Activated
11-03-2017
ClinicalTrials.gov Registry Number
NCT03228537
Open
Phase
II
Accrual
9%
SWOG Clinical Trial Number
S1613

A Randomized Phase II Study of Pertuzumab and Trastuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification

Status Notes
Effective 10/09/2017 at 2pm Eastern, S1613 will be active for accrual.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-09-2017
Open
Phase
II
Accrual
36%
SWOG Clinical Trial Number
S1400F

A PHASE II STUDY OF MEDI4736 AND TREMELIMUMAB AS THERAPY FOR CHECKPOINT INHIBITOR REFRACTORY SQUAMOUS PATIENTS

Status Notes
Effective immediately on 11/3/17, S1400F will be re-opened for patient accrual.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Research Committee(s)
Lung Cancer
Activated
10-02-2017
Open
Phase
II
Accrual
12%
SWOG Clinical Trial Number
S1607

A Phase II Study Of Combining Talimogene laherparepvec (T-VEC) And PD-1 Blockade With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On Anti-PD1 Therapy

Status Notes
Effective 10/02/2017 at 2pm Eastern, S1607 will be active for accrual.
Research Committee(s)
Melanoma
Activated
10-02-2017
ClinicalTrials.gov Registry Number
NCT02965716
Open
SWOG Clinical Trial Number
S1400 VCP

S1400 Version Control Protocol

Status Notes
The purpose of this memorandum is to notify sites that the new administrative protocol S1400VCP (Version Control Protocol) is now available on the S1400 Abstract Page Links on the SWOG website (http://swog.org).

The intent of the S1400VCP is to allow an individual sub-study to be revised independently of the other sub-studies. The S1400VCP keeps track of revisions or updates made to the various sub-studies and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each component of Lung-MAP associated with each revision or update.

Sites may use this document to verify the most current version of a sub-study, and may also reference this document for an overview of Lung-MAP revisions.
Research Committee(s)
Lung Cancer
Activated
09-22-2017
Open
Accrual
6%
SWOG Clinical Trial Number
S1501

Prospective Evaluation of Carvedilol vs No treatment in Prevention of Cardiac Dysfunction in Women with Metastatic HER-2+ Breast Cancer.

Status Notes
This study is open to accrual effective September 15, 2017 at 2:00 p.m. Pacific.

For questions you may email the study team at: F1501dhrfgvba/ng/fjbt/qbg/bet
Research Committee(s)
Cancer Survivorship
Breast Cancer
Activated
09-15-2017
ClinicalTrials.gov Registry Number
NCT03418961
Open
Phase
III
SWOG Clinical Trial Number
CTSU/EA8134

InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Status Notes
This study is open to accrual effective September 8, 2017.
Research Committee(s)
Genitourinary Cancer
Activated
09-08-2017
Open
Phase
Accrual
7%
SWOG Clinical Trial Number
S1608

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Status Notes
11/1/2018 - A Physician Protocol Card and Physician Handout, reflecting changes made with Revision 3 are now accessible from the protocol abstract page below and will be posted to CTSU protocol abstract page at www.ctsu.org.

Effective with release of Revision #3 (10/2/2018):

The intent of Revision #3 is to provide increased opportunity for accrual. The revision expands the eligibility criteria to include follicular lymphoma patients that relapsed within 2 years of completing their first course of chemotherapy (1 course, containing at least 3 cycles of either CHOP or bendamustine-based therapy) + anti-CD20 therapy.

Arm 3 treatment will now be comprised of either CHOP + Obinutuzumab or Bendamustine + Obinutuzumab. That is, the Arm 3 treatment regimen is dependent upon the first course of chemotherapy that the patient received prior to registration to S1608.

Patients who were treated with bendamustine prior to registration (and who are randomized to Arm 3) will receive CHOP + Obinutuzumab. Conversely, patients who were treated with CHOP prior to registration (and who are randomized to Arm 3) will receive Bendamustine + Obinutuzumab.
Research Committee(s)
Lymphoma
Activated
08-10-2017
Open
Phase
III